These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 8048751)

  • 1. [Markers in lung cancer].
    Balibrea JL
    An R Acad Nac Med (Madr); 1993; 110(4):585-603; discussion 604-5. PubMed ID: 8048751
    [No Abstract]   [Full Text] [Related]  

  • 2. Interference with netrin-1 and tumor cell death in non-small cell lung cancer.
    Delloye-Bourgeois C; Brambilla E; Coissieux MM; Guenebeaud C; Pedeux R; Firlej V; Cabon F; Brambilla C; Mehlen P; Bernet A
    J Natl Cancer Inst; 2009 Feb; 101(4):237-47. PubMed ID: 19211441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of the tumor suppressor gene maspin in non-small cell lung cancer.
    Hirai K; Koizumi K; Haraguchi S; Hirata T; Mikami I; Fukushima M; Yamagishi S; Kawashima T; Okada D; Shimizu K; Kawamoto M
    Ann Thorac Surg; 2005 Jan; 79(1):248-53. PubMed ID: 15620951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The role of tumor markers in the pre-therapeutic staging of non-small cell bronchial cancer].
    Biron P
    Rev Mal Respir; 1992; 9 Suppl 4():R299-304. PubMed ID: 1336877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer procoagulant (CP) in lung cancer.
    Rucińska M; Skrzydlewski Z; Zaremba E; Furman M; Kasacka I
    Rocz Akad Med Bialymst; 1997; 42 Suppl 1():251-3. PubMed ID: 9337542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic significance of neuroendocrine markers and carcinoembryonic antigen in patients with resected stage I and II non-small cell lung cancer.
    Graziano SL; Tatum AH; Newman NB; Oler A; Kohman LJ; Veit LJ; Gamble GP; Coleman MJ; Barmada S; O'Lear S
    Cancer Res; 1994 Jun; 54(11):2908-13. PubMed ID: 8187076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hierarchical clustering of lung cancer cell lines using DNA methylation markers.
    Virmani AK; Tsou JA; Siegmund KD; Shen LY; Long TI; Laird PW; Gazdar AF; Laird-Offringa IA
    Cancer Epidemiol Biomarkers Prev; 2002 Mar; 11(3):291-7. PubMed ID: 11895880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clonogenic culture of identified cells of lung tumors and correlation with certain histopathologic aspects of the tumor mass].
    Gotzos V; Hahnloser P; Petropoulos P
    Helv Chir Acta; 1991 Feb; 57(5):725-9. PubMed ID: 1650768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immunohistochemistry of biomolecular markers of lung cancer].
    Kogan EA; Zhak G; Kaĭzer U; Shilli M; Shurman M; Sherer A; Khavemann K
    Arkh Patol; 1997; 59(6):23-30. PubMed ID: 9483214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methylation of RAS association domain family protein 1A as a biomarker of lung cancer.
    Grote HJ; Schmiemann V; Geddert H; Bocking A; Kappes R; Gabbert HE; Sarbia M
    Cancer; 2006 Apr; 108(2):129-34. PubMed ID: 16444703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transferrin receptor expression in nonsmall cell lung cancer: histopathologic and clinical correlates.
    Carbognani P; Rusca M; Romani A; Spaggiari L; Cattelani L; Solli P; Bobbio P
    Cancer; 1996 Jul; 78(1):178-9. PubMed ID: 8646716
    [No Abstract]   [Full Text] [Related]  

  • 12. Cytokines and chemokines as predictive markers in non-small cell lung cancer patients with brain metastases.
    Altundag O; Altundag K; Morandi P; Gunduz M
    Lung Cancer; 2005 Feb; 47(2):291-2. PubMed ID: 15639730
    [No Abstract]   [Full Text] [Related]  

  • 13. Evaluations of p53 immunoreactivity, nucleolar organizer regions, and proliferating cell nuclear antigen in non-small cell lung carcinoma.
    Oyama T; Osaki T; Nose N; Ichiki Y; Inoue M; Imoto H; Yoshimatsu T; Kodate M; Uramoto H; Mizoue T; Yano K; Yasumoto K
    Anticancer Res; 2000; 20(1B):505-10. PubMed ID: 10769714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor infiltrating lymphocytes and macrophages have a potential dual role in lung cancer by supporting both host-defense and tumor progression.
    Kataki A; Scheid P; Piet M; Marie B; Martinet N; Martinet Y; Vignaud JM
    J Lab Clin Med; 2002 Nov; 140(5):320-8. PubMed ID: 12434133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New challenges for laboratory diagnostics in non-small cell lung cancer.
    Holdenrieder S; Stieber P
    Cancer Biomark; 2010; 6(3-4):119-21. PubMed ID: 20660958
    [No Abstract]   [Full Text] [Related]  

  • 16. Stratification of the biologic aggressiveness of non-small cell lung cancer using DNA flow cytometry and immunohistochemistry for the retinoblastoma protein.
    Otsuka H; Funai S; Tanaka A; Hara S; Shiozaki H
    Lung Cancer; 2004 Sep; 45(3):307-16. PubMed ID: 15301871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antigens, receptors and dominant oncogenes and the prognosis of non-small cell lung cancer.
    Stahel RA
    Lung Cancer; 1994 Nov; 11 Suppl 3():S31-8. PubMed ID: 7704510
    [No Abstract]   [Full Text] [Related]  

  • 18. Quantification of macrophage migration inhibitory factor mRNA expression in non-small cell lung cancer tissues and its clinical significance.
    Tomiyasu M; Yoshino I; Suemitsu R; Okamoto T; Sugimachi K
    Clin Cancer Res; 2002 Dec; 8(12):3755-60. PubMed ID: 12473586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of features of human lung cancer cell lines and their corresponding tumors.
    Wistuba II; Bryant D; Behrens C; Milchgrub S; Virmani AK; Ashfaq R; Minna JD; Gazdar AF
    Clin Cancer Res; 1999 May; 5(5):991-1000. PubMed ID: 10353731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53 Gene status in relation to ex vivo chemosensitivity of non-small cell lung cancer.
    Vogt U; Zaczek A; Klinke F; Granetzny A; Bielawski K; Falkiewicz B
    J Cancer Res Clin Oncol; 2002 Mar; 128(3):141-7. PubMed ID: 11935300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.